v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Operating expenses        
Research and development $ 12,473 $ 5,118 $ 21,807 $ 9,192
General and administrative 8,932 4,132 14,453 7,929
Total operating expenses 21,405 9,250 36,260 17,121
Operating loss (21,405) (9,250) (36,260) (17,121)
Other (expense) income:        
Interest expense - royalty agreement (2,308) (1,354) (4,347) (2,569)
Fair value adjustments on derivative liabilities - royalty agreement (114) (118) (230) (193)
Fair value adjustments on derivative liabilities - contingent value right liability 0 0 202 0
Interest income, net 1,965 690 3,038 1,442
Other (expense) income, net (8) 561 (40) 785
Loss before income taxes (21,870) (9,471) (37,637) (17,656)
Income tax benefit (expense) 0 0 0 0
Net loss (21,870) (9,471) (37,637) (17,656)
Other comprehensive loss:        
Unrealized loss on investments (30) 0 (26) 0
Foreign currency translation gain (loss) 24 (108) 32 (114)
Comprehensive loss $ (21,876) $ (9,579) $ (37,631) $ (17,770)
Net loss per share of Common Stock - basic (in dollars per share) $ (1.52) $ (0.86) $ (2.74) $ (1.6)
Net loss per share of Common Stock - diluted (in dollars per share) $ (1.52) $ (0.86) $ (2.74) $ (1.6)
Weighted-average shares used in computing net loss per share of Common Stock - basic (in shares) 14,356,219 11,052,741 13,724,256 11,033,327
Weighted-average shares used in computing net loss per share of Common Stock - diluted (in shares) 14,356,219 11,052,741 13,724,256 11,033,327